-
SBI & the Microbiome
Serum-derived bovine immunoglobulin/protein isolate (SBI) may have a prebiotic mechanism of action, resulting in an increase in short-chain fatty acid production (SCFA), as published in Microorganisms. SBI is a concentrated form of immunoglobulins that has several clinical trials demonstrating benefits for IBS, IBD, and enteropathy, but its mechanisms of action may only be partially understood,…
-
SBI Cost Savings for IBD Patients
A pilot study has provided evidence of the cost-saving benefits of the incorporation of serum-derived bovine immunoglobulin/protein isolate (SBI) into the therapeutic regimen of people with inflammatory bowel disease (IBD).
-
Pouchitis & SBI
Compelling research has shown positive outcomes for patients suffering from pouchitis using Serum-Derived Bovine Immunoglobulin/Protein isolate (SBI) therapy.
-
IBD Management & SBI
A retrospective case series review of people with Crohn’s disease (CD) and ulcerative colitis (UC) whose symptoms weren’t controlled by traditional pharmaceutical therapies showed a symptom improvement rate of 76% after 12 weeks of taking serum-derived bovine immunoglobulin (SBI).
-
IBS Case Responses to SBI
A case series of 10 patients with long-standing, symptomatic, intractable drug-refractory irritable bowel syndrome (IBS) were given dietary support and a serum-derived bovine immunoglobulin/protein isolate (SBI) and reported an average of 69% complete management of IBS-related symptoms.
-
Post-Infectious IBS-D & SBI
A small double-blind study has revealed serum-derived bovine immunoglobulin (SBI) as a potentially safe, effective nutritional moiety in post-infectious, refractory diarrhea-predominant irritable bowel syndrome (IBS-D) and IBS with a mixed diarrhea/constipation pattern (IBS-M).